is one report of lower neurodevelopmental scores in

preterm infants (n = 103; <31 weeks’ gestational age)

associated with repeated doses of sucrose for analgesia

(39). The safe maximum dose of sucrose is unknown.

I. Contraindications

1. There are no absolute contraindications to using analgesia and/or sedation when deemed clinically appropriate.

2. Be aware of the potential side effects associated with the

specific agent selected and take the proper precautions.

References

1. Lemons JA, Blackmon LR, Kanto WP, et al. American Academy

of Pediatrics: Prevention and Management of Pain in the Neonate:

An Update. http://aappolicy.aappublications.org/cgi/content/full/

pediatrics;118/5/2231. Accessed August 7, 2011.

2. Anand KJS. Clinical importance of pain and stress in preterm

neonates. Biol Neonate. 1998;73:1.

3. Anand KJS, Hickey PR. Pain and its effects in the human neonate

and fetus. N Engl J Med. 1987;317:1321.

4. Simons SH, van Dijk M, Anand KS, et al. Do we still hurt newborn babies? A prospective study of procedural pain and analgesia

in neonates. Arch Pediatr Adolesc Med. 2003;157:1058.

5. Tutag Lehr V, Taddio A. Practical approach to topical anesthetics

in the neonate. Semin Perinatol. 2007;31:323.

6. Anand KJS, Johnston CC, Oberlander TF, et al. Analgesia and

local anesthesia during invasive procedures in the neonate. Clin

Ther. 2005;27:884.

7. Vitali SH, Camerota AJ, Arnold JH. Anaesthesia and analgesia in

the newborn. In: Macdonald MG, Mullett MD, Sechia MMK,

eds. Neonatology: Pathophysiology and Management of the

Newborn. 6th ed. Philadelphia: Lippincott Williams & Wilkins;

2005:1557.

8. Mathew PJ, Mathew JL. Assessment and management of pain in

infants. Postgrad Med J. 2003;79:438.

9. Porter FL, Wolf CM, Gold J, et al. Pain and pain management in

newborn infants: a survey of physicians and nurses. Pediatrics.

1997;100:626.

10. McLaughlin CK, Hull JG, Edwards WH, et al. Neonatal pain: a

comprehensive survey of attitudes and practices. J Pain Symptom

Manage. 1993;8:7.

11. Barker DP, Rutter N. Exposure to invasive procedures in neonatal

intensive care unit admission. Arch Dis Child Fetal Neonatal Ed.

1995;72:47.

12. Leeder JS. Developmental and pediatric pharmacogenomics.

Pharmacogenomics. 2003;4:331.

13. Warrier I, Du W, Natarajan G, et al. Patterns of drug utilization in

a neonatal intensive care unit. J Clin Pharmacol. 2006;46:449.

14. Anand KJS, Aranda JV, Berde CB, et al. Analgesia for Neonates:

study design and ethical issues. Clin Ther. 2005;27:814.

15. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental

pharmacology. N Engl J Med. 2003;349:1157.

42 Section I ■ Preparation and Support

16. Bjorkman S. Prediction of drug disposition in infants and children

by means of physiologically based pharmacokinetic (PBPK) modeling: theophylline and midazolam as model drugs. Br J Clin

Pharmacol. 2005;59:691.

17. Johnson CC, Collinge JM, Henderson SJ, et al. A cross-sectional

survey of pain and pharmacological analgesia in Canadian neonatal intensive care units. Clin J Pain. 1997;13:308.

18. Stevens BJ, Pillai RR, Oberlander TE, et al. Assessment of pain in

neonates and infants. In: Anand KJS, Stevens BJ, McGrath PJ,

eds. Pain in Neonates and Infants. 3rd ed. Edinburgh: Elsevier;

2007:67.

19. Hummel P, Puchalski M, Creech SD, et al. Clinical reliability

and validity of the N-PASS: neonatal pain, agitation and sedation

scale with prolonged pain. J Perinatol. 2008;28:55.

20. Johnston CC, Stevens BJ, Yang F, et al. Differential response to

pain by very premature infants. Pain. 1995;61:471.

21. Aranda JV, Carlo W, Hummel P, et al. Analgesia and sedation

during mechanical ventilation in neonates. Clin Ther. 2005;

27:877.

22. Anand KJ, Barton BA, McIntosh N, et al. Analgesia and sedation

in preterm neonates who require ventilatory support: results of the

NOPAIN trial. Neonatal Outcome and Prolonged Analgesia In

Neonates. Arch Pediatr Adolesc Med. 1999;153:331.

23. American Psychiatric Association. Diagnostic and Statistical

Manual of Mental Disorders. 4th ed. text rev. Washington, DC:

American Psychiatric Press; 2000.

24. Franck L, Vilardi J. Assessment and management of opioid withdrawal in ill neonates. Neonatal Netw. 1995;14:39.

25. McRae ME, Rourke DA, Imperial-Perez FA, et al. Development

of a research-based standard for assessment, intervention, and

evaluation of pain after neonatal and pediatric cardiac surgery.

Pediatr Nurs. 1997;23:263.

26. Cote CJ, Karl HW, Notterman DA, et al. Adverse sedation events

in pediatrics: analysis of medications used for sedation. Pediatrics.

2000;106:633.

27. Cote CJ, Notterman DA, Karl HW, et al. Adverse sedation events

in pediatrics: a critical incident analysis of contributing factors.

Pediatrics. 2000;105:805.

28. Morriss FG, Abramowitz PW, Nelson PS, et al. Risk of adverse

drug events in neonates treated with opioids and the effect of a

bar-code-assisted medication administration system. Am J Health

Syst Pharm. 2011;68:57.

29. Barrett DA, Barker DP, Rutter N, et al. Morphine, morphine-6-

glucuronide, morphine-3-glucuronide pharmacokinetics in new

born infants receiving diamorphine infusions. Br J Clin

Pharmacol. 1996;41:531.

30. Bhat R, Abu-Harb M, Chari G, et al. Morphine metabolism in

acutely ill preterm newborn infants. J Pediatr. 1992;120:795.

31. Bjorkman S. Prediction of drug disposition in infants and children

by means of physiologically based pharmacokinetic (PBPK) modeling: theophylline and midazolam as model drugs. Br J Clin

Pharmacol. 2005;59:691.

32. Shah PS, Shah VS. Propofol for procedural sedation/anaesthesia

in neonates. Cochrane Database Syst Rev. 2011;(3): CD007248.

33. Chana SK, Anand KJS. Can we use methadone for analgesia in

preterm infants? Arch Dis Child Fetal Neonatal Ed. 2001;85:F79

doi:10.1136/fn.85.2.F79.

34. Jacqz-Aigrain E, Burtin P. Clinical pharmacokinetics of sedatives

in neonates. Clin Pharmacokinet. 1997;36:449.

35. Frank LS, Vilardi J, Durand D, et al. Opioid withdrawal in neonates after continuous infusions of morphine or fentanyl during

extracorporeal membrane oxygenation (ECMO). Am J Crit Care.

1998;7:364.

36. Lambert GH, Muraskas J, Anderson CL, et al. Direct hyperbilirubinemia associated with chloral hydrate administration in the

newborn. Pediatrics. 1990;86:277.

37. Reimche LD, Sankaran K, Hindmarsh KW, et al. Chloral hydrate

sedation in neonates and infants—clinical and pharmacologic

considerations. Dev Pharmacol Ther. 1989;12:57.

38. Mayers DJ, Hindmarsh KW, Sankaran K, et al. Chloral hydrate

disposition following single-dose administration to critically ill

neonates and children. Dev Pharmacol Ther. 1991;16:71.

39. Johnston CC, Filinon F, Snider L, et al. Routine sucrose analgesia during the first week of life in neonates younger than 31 weeks

postconceptual age. Pediatrics. 2002;110:523.

43

7 Temperature Monitoring

8 Cardiorespiratory Monitoring

9 Blood Pressure Monitoring

10 Continuous Blood Gas Monitoring

11 End-Tidal Carbon Dioxide Monitoring

12 Transcutaneous Bilirubin Monitoring

II Physiologic

Monitoring